By Maggie Fick and Bhanvi Satija

LONDON (Reuters) -Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in its key drugs Ozempic and Wegovy, in a deal that some analysts said sounded less onerous than feared.

The U.S. Inflation Reduction Act requires pharmaceutical companies to negotiate drug prices with the Medicare health insurance programme, which covers more than 60 million people.

The price will take effect in 2027. The announcement came alongside Novo’s third-quarter earnings and a cut to its 2025 financial guidance for the fourth time this year.

It also comes the day after a White House source said Novo and U.S. rival Eli Lilly were expected to announce deals this week with the Trump administration to cut pric

See Full Page